Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug;44(8):2963-2965.
doi: 10.1007/s10072-023-06780-2. Epub 2023 Mar 29.

On a 5-year-old girl with multiple sclerosis treated with natalizumab

Stefano Sotgiu  1 , Arianna Nieddu  2 , Dario Pruna  3 , Arianna Madrau  2 , Ignazio Roberto Zarbo  4 , Alessandra Carta  2
Affiliations
Case Reports

On a 5-year-old girl with multiple sclerosis treated with natalizumab

Stefano Sotgiu et al. Neurol Sci. 2023 Aug.
No abstract available

PubMed Disclaimer

References

    1. Gorman MP, Healy BC, Polgar-Turcsany M, Chitnis T (2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 66:54–59 - DOI - PubMed
    1. Baroncini D, Simone M, Iaffaldano P, Italian MS, registry, et al (2021) Risk of persistent disability in patients with pediatric-onset multiple sclerosis. JAMA Neurol 78:726–735 - DOI - PubMed
    1. Ghezzi A, Banwell B, Boyko A et al (2010) The management of multiple sclerosis in children: a European view. Mult Scler 16:1258–1267 - DOI - PubMed
    1. Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173 - DOI - PubMed
    1. Baroncini D, Ghezzi A, Guaschino C et al (2022) MS Study Group of the Italian Neurological Society. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. Neurol Sci 43:6415–6423 - DOI - PubMed

MeSH terms

LinkOut - more resources